Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1530165 | 0.82 | ESR1 (0.39) | APPCA1CA2MEN1KMT2A | |
| SCHEMBL7034982 | 0.81 | KMT2A (0.47) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2472803 | 0.80 | MEN1 (0.43) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1064506 | 0.80 | TDP1 (0.41) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5480662 | 0.80 | RECQL (0.41) | APPMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL16594120 | 0.80 | KMT2A (0.42) | CA1CA2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5526810 | 0.78 | MAPT (0.44) | MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16279882 | 0.78 | KMT2A (0.41) | MEN1KMT2ASMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL1025144 | 0.78 | SCN2A (0.39) | APPMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL2497436 | 0.77 | EPHX2 (0.44) | APPTRPV1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745261-B2 | Inhibitors of the MITF molecular pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9403803-B2 | Indole-3-carboxamides as kinase inhibitors | ALLERGAN, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE BROAD INSTITUTE, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9321766-B1 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160102077-A1 | Indole-3-Carboxamides as Kinase Inhibitors | ALLERGAN, INC. | 2016-04-14 | — | — | US | disclosed |
| US-20160096832-A1 | KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | MITF, TFEB, TYR | TPMT 3749/4885APP 4618/4885CA1 4875/4885 |
| US-20160102077-A1 | Indole-3-Carboxamides as Kinase Inhibitors | JAK2, REN, IGF1R | TPMT 2371/4885APP 4558/4885CA1 4613/4885 |
| US-20160096832-A1 | KINASE INHIBITORS | ABL1, LCK, ERBB2 | TPMT 1219/4885APP 4759/4885CA1 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.